PharmaFocus Today – Page 611 – media

UBS buys Credit Suisse for $3.2 billion as regulators look to shore up the global banking system

The Financial Times reported that UBS has agreed to buy the bank for more than $2 billion, a substantial increase from the initial $1 billion offer it reported earlier Sunday. UBS agreed to buy its embattled rival Credit Suisse for $3.2 billion Sunday, with Swiss regulators playing a key part in the deal as governments looked to stem a contagion threatening the global banking system. “With the takeover of Credit Suisse by UBS, a solution has been found to secure financial stability and protect the Swiss economy in this exceptional situation,” read a statement from the Swiss National Bank, which noted the central bank worked with the Swiss government and the Swiss Financial Market Supervisory Authority to bring about the combination of the country’s two largest banks. The terms of the deal will see Credit Suisse shareholders receive 1 UBS share for every 22.48 Credit Suisse shares they hold. “This ...
- Source: drugdu
- 614
- March 20, 2023
Organoid Intelligence

Researchers just announced a plan to eventually create “organoid intelligence,” or OI. They plan to grow clumps of brain cells called organoids and create technology that would allow us to turn those clumps of cells into powerful and efficient computers. The technology is only in its infancy, but it has implications for everything from computer memory to neurological diagnostics. The human brain is a wonderful and complicated organ. Despite decades of study and scientific progress, there’s still a lot we don’t know about how it works and why it behaves the way it does. But we know it’s powerful. It might not be as quick to solve complex equations as a computer, but it’s wildly more energy-efficient and significantly better at both learning and memory. And recently, researchers have been looking into how combine a brain and a computer, giving us the power of a human mind at our fingertips. ...
- Source: drugdu
- 713
- March 20, 2023
New Study Shows Promising Results for Targeted Cancer Therapy

A recent study published in the Journal of Clinical Oncology has shown promising results for a new type of cancer therapy. The therapy, known as a targeted therapy, uses drugs that specifically target the genetic mutations that drive the growth of cancer cells. Traditional cancer treatments like chemotherapy and radiation therapy are often associated with serious side effects because they damage healthy cells along with cancer cells. Targeted therapies, on the other hand, are designed to be more precise and have fewer side effects. The new study focused on a targeted therapy called larotrectinib, which is designed to treat cancers that have a specific genetic mutation called NTRK fusion. NTRK fusion is a rare but important genetic alteration that is found in a variety of cancers, including certain types of lung, colon, and breast cancer. The study included 55 patients with NTRK fusion-positive cancer who were treated with larotrectinib. The ...
- Source: drugdu
- 482
- March 20, 2023
New Study Shows Potential for Personalized Treatment for Lung Cancer

Lung cancer is a leading cause of cancer-related death worldwide, and treatment options are limited for patients with advanced disease. However, a recent study published in the journal Nature has shown promising results for a new approach to treating lung cancer using personalized medicine. The researchers analyzed the genomes of more than 2,000 patients with non-small cell lung cancer and identified several genetic mutations that were associated with a better response to immunotherapy, a type of cancer treatment that helps the immune system fight cancer. The researchers also developed a personalized treatment algorithm that took into account the genetic mutations of each patient’s tumor. They found that patients who received personalized treatment based on their tumor’s genetic profile had a better response to immunotherapy than those who received standard treatment. The lead author of the study, Dr. Trever Bivona, said that the results were “very promising” and showed that personalized ...
- Source: drugdu
- 410
- March 20, 2023
New Study Shows Potential for Gene Therapy to Treat Duchenne Muscular Dystrophy

Duchenne muscular dystrophy (DMD) is a rare and devastating genetic disorder that causes progressive muscle weakness and eventually leads to death. There is currently no cure for DMD and available treatments only offer modest benefits. However, a recent study published in the journal Nature has shown promising results for a new approach to treating DMD using gene therapy. The researchers used a viral vector to deliver a functional copy of the dystrophin gene, which is mutated in DMD, to muscle cells in mice with the disease. The researchers found that the gene therapy led to an improvement in muscle strength and function in the mice. They also found that the therapy was safe and well-tolerated. The lead author of the study, Dr. Dongsheng Duan, said that the results were “very encouraging” and showed that gene therapy could be a viable option for treating DMD. “This study demonstrates that gene therapy ...
- Source: drugdu
- 413
- March 20, 2023
Researchers Identify Potential New Drug Target for Treating Depression

Depression is a common and debilitating mental illness that affects millions of people worldwide. While there are several effective treatments for depression, many patients do not respond to these treatments or experience side effects. A recent study published in the journal Nature Communications has identified a potential new drug target for treating depression. The researchers focused on a protein called L-type calcium channel α1D, which plays a key role in the regulation of mood-related behaviors. Using a mouse model of depression, the researchers found that blocking the activity of this protein led to an improvement in depressive symptoms. They also found that the protein was overactive in the brains of depressed mice and in post-mortem brain tissue from people with depression. The lead author of the study, Dr. Jian Feng, said that the results were “exciting” and showed that targeting this protein could be a promising new approach to treating ...
- Source: drugdu
- 434
- March 20, 2023
NICE approves funding for Novartis gene therapy

Funding is for onasemnogene abeparvovec and concerns babies with spinal muscular atrophy NICE has published final draft guidance regarding the recommendation of routine NHS funding for onasemnogene abeparvovec. The treatment is a potentially curative one-off gene therapy for treating a rare genetic condition, spinal muscular atrophy (SMA). It will be used specifically among babies aged up to 12 months, before they develop symptoms. The drug – also known as Zolgensma – is produced by Novartis Gene Therapies. The recommendation has emerged after NICE reviewed the evidence to determine whether it should be available for routine NHS funding in England and Wales. Onasemnogene abeparvovec is designed to address the genetic cause of SMA and its effects are thought to be life-long. Under NICE’s original guidance, released in 2021, it was recommended for babies before they develop symptoms of SMA as part of a managed access agreement (MAA). The agreement ensured that ...
- Source: drugdu
- 437
- March 17, 2023
Brazil’s ANVISA approves Takeda’s dengue vaccine Qdenga

Qdenga’s approval is supported by the data obtained from 19 clinical trials, and follows similar decisions in other countries. The National Health Surveillance Agency (ANVISA) in Brazil has granted approval for Takeda’s tetravalent dengue virus vaccine, Qdenga. The vaccine, previously known as TAK-003, has received approval for preventing dengue disease in people aged four years to 60 years. Qdenga has been developed based on a live-attenuated dengue serotype 2 virus that offers the genetic backbone for four dengue virus serotypes and is designed to provide protection against any of these. Qdenga is purported to be the only dengue vaccine approved in Brazil for use in people without the need for pre-vaccination testing and regardless of previous exposure. ANVISA’s approval follows similar decisions by the European Commission in December, and the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) last month. The company continues to advance regulatory filings in other dengue-endemic countries in Asia and Latin America. In ...
- Source: drugdu
- 680
- March 17, 2023
Healthcare companies may turn to big banks after SVB’s fall

Healthcare startups may turn to traditional large banks and prioritize conserving cash after the collapse of regional lenders Silicon Valley Bank and Signature Bank last week. The fall of SVB created a hole in the life sciences startup sector, locking out funds temporarily for some companies and cutting off a source of short-term cash for healthcare startups. A major bank and lender for healthcare companies, SVB last year had clients in nearly half of U.S. venture-backed technology and life sciences companies. “At this very moment, I think most of the companies are flying to safety, to the big banks,” said Ian Chiang, partner at healthcare investing company Flare Capital, “Perhaps it’s a little bit of a knee-jerk reaction to see what would happen.” However, companies may still deposit with regional banks, depending on size. Healthcare unicorns, meaning companies with valuations exceeding $1 billion, are likely not going to be able to have ...
- Source: drugdu
- 507
- March 17, 2023
China’s NMPA accepts GSK’s drug application review for Nucala to treat SEA

China National Medical Products Administration has accepted the review of GSK’s drug application for Nucala (mepolizumab) as an add-on maintenance treatment for severe eosinophilic asthma (SEA). If given approval, Nucala will become the first targeted anti-Interleukin-5 (IL-5) treatment in the country for adult and adolescent patients with SEA. A first-in-class monoclonal antibody to target IL-5, Nucala was first approved in 2015 for SEA in the US. It prevents IL-5 from binding to its receptor on the surface of eosinophils, lowering blood eosinophils and maintains them under normal levels. The application to China National Medical Products Administration has been submitted based on positive data from Phase III trial undertaken on patients in China and the global SEA development programme, which included three important clinical trials – DREAM 2, MENSA3 and SIRIUS4. These trials established the efficacy and safety profile of mepolizumab for SEA patients. The Phase III trial for 52 weeks studied the ...
- Source: drugdu
- 373
- March 16, 2023

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.